Division of General Internal Medicine and Public Health

September 30, 2015

Reduced-nicotine cigarettes decreased dependence and frequency of smoking: NEJM study

Reduced-nicotine cigarettes were beneficial in reducing nicotine exposure and dependence, and also the number of cigarettes smoked per day, when compared with standard-nicotine cigarettes in a six-week study published in the New England Journal of Medicine.

August 13, 2015

Grant bolsters Clinical Data Research Network

The Mid-South Clinical Data Research Network, led by Vanderbilt University’s Russell Rothman, M.D., M.P.P., has been approved for a three-year, $8.5 million funding award from the independent Patient-Centered Outcomes Research Institute (PCORI) to expand its efforts to improve healthcare throughout the Southeast.

August 6, 2015

Rothman named to lead population health research efforts

Russell Rothman, M.D., MPP, professor of Medicine, Pediatrics and Health Policy, chief of the Section of Internal Medicine and Pediatrics and director of the Vanderbilt Center for Health Services Research, has been named assistant vice chancellor for Population Health Research.

March 12, 2015

Panel examines real-world role of pragmatic research trials

The question of what’s different about pragmatic research was aired in a well-attended panel discussion last week in Light Hall sponsored by the Vanderbilt Center for Health Services Research and the Mid-South Clinical Data Research Network (CDRN).

November 20, 2014

Tindle to direct Tobacco Research and Treatment

November is well-known as Lung Cancer Awareness Month. It is also the month that highlights awareness of less publicized forms of cancer including pancreatic cancer and stomach cancer.

Insulin in vials
June 12, 2014

Study tracks insulin’s risks as second-line diabetes medication

In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.